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The pandemic H1N1/09 emerged rapidly in Korea. Here, we describe the clinical 
characteristics of outpatients in Seoul, Korea who were infected in the 2009 H1N1 
pandemic. We reviewed the cases of outpatients with pandemic H1N1/09 who vis-
ited a tertiary care teaching hospital between September 1 and December 31, 
2009. Infection with pandemic H1N1/09 was confirmed by molecular tests. Of a 
total of 7,182 tests, 3,020 (42.0%) were positive. Compared with 473 cases of in-
fluenza-like illness (ILI), the 586 confirmed cases of pandemic H1N1/09 differed 
in age [odds ratio (OR) 0.975] and fulfilling at least one of the following factors: 
age <5 or ≥65 years, history of contact with other pandemic H1N1/09-infected in-
dividuals (OR 0.611), fever ≥37.8°C (OR 3.567), cough (OR 2.290), and myalgia 
(OR 1.559). The sensitivity of the best criteria, “fever (≥37.8°C) plus cough” 
(41.03%) in this study was lower than that of the Korea Centers for Disease Con-
trol and Prevention (KCDC) criteria (47.95%), whereas the positive likelihood ra-
tio (3.55) and positive predictive value (81.6) of this criteria was higher than those 
of the KCDC criteria (2.98 and 78.7, respectively). The clinical characteristics of 
pandemic H1N1/09 are, in many regards, indistinguishable from those of ILI. 
Moreover, the accuracy and predictability of criteria which include only symptoms 
or signs were not sufficient to diagnose pandemic H1N1/09 infection. Therefore, 
use of a combination of symptoms with confirmatory laboratory testing is neces-
sary for accurate diagnosis of pandemic H1N1/09.
Key Words:    Influenza A virus, H1N1 subtype, pandemic H1N1/09, outpatients, 
characteristics
The first case of pandemic H1N1/09 in Korea was identified on May 2, 2009. Af-
ter that time, the number of confirmed cases increased steadily; according to the 
reports of the Korea Centers for Disease Control and Prevention (KCDC), which 
operates the Korean emergency response system, a total of 2,417 cases had been 
reported by August 19, 2009.1 Beginning August 21, 2009, the KCDC shifted its 
strategy from containment to mitigation and altered the antiviral agent prescription 
guidelines to allow clinicians to prescribe antiviral agents to all patients with Kyung Sun Park, et al.
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The KCDC criteria for suspicion of pandemic H1N1/09 
infection were cases in which patients suffered from an unex-
plained fever (defined by an ear temperature ≥37.8°C or anti-
pyretics within 12 hours before hospital visit) within seven 
days before visiting the hospital and displayed symptoms 
such as a cough, sore throat, rhinorrhea, or nasal obstruction. 
Statistical analysis was conducted using SPSS Statistics 
version 12.0 (SPSS, Inc., Chicago, IL, USA). We conduct-
ed t-tests for quantitative data, chi-square or Fisher’s exact 
tests for qualitative data, depending on the anticipated cell 
number, and Cochran Mantel-Haenzel tests for investigat-
ing the confounding variable of age. Multivariate logistic 
regression analyses were employed to evaluate the indepen-
dent risk factors for pandemic H1N1/09-positive status by 
backward (wald) stepwise logistic regression models. Only 
the variables with p<0.1 by univariate analysis were includ-
ed in the multivariate analysis. Finally, a p-value <0.05 was 
considered to be indicative of statistical significance. We 
then calculated sensitivity, specificity, area under the ROC 
curve (AUC), positive likelihood ratios (PLR), negative 
likelihood ratios (NLR), positive predictive value (PPV), 
and negative predictive value (NPV) of the possible diag-
nostic criteria to identify those that were best for pandemic 
H1N1/09.
Between September 1 and December 31, confirmed-PCR 
tests for pandemic H1N1/09 were performed for a total of 
7,182 patients (Fig. 1). Of these, 3,020 (42.0%) were posi-
tive. We randomly selected 1,458 individuals (approximate-
ly 20%) using SPSS Statistics. Of these, we excluded 399 
inpatients, patients without detailed information about the 
symptoms of influenza-like illness without a laboratory di-
agnosis.2 Moreover, after that time, the KCDC did not con-
duct individual epidemiologic investigations of confirmed 
cases. The incidence of influenza-like illness (ILI) and con-
sumption of antiviral agents peaked in early November.2
The initial literature concerning the pandemic H1N1/09 
infection associated the strain with profound morbidity and 
mortality.3-7 However, data on outpatients infected with 
pandemic H1N1/09 are still lacking. In this study, we de-
scribe the clinical characteristics of outpatients with pan-
demic H1N1/09 during the mitigation period at a tertiary 
university hospital in Korea. 
We conducted a retrospective review of the presentation 
of outpatients with ILI at Kyung Hee University Hospital 
between September and December 2009. This study was 
approved by the IRB. In the vast majority of patients with 
ILI, pandemic H1N1/09 infection was confirmed by labora-
tory testing. Written informed consent was obtained from 
all participants. The department of laboratory medicine at 
Kyung Hee University Hospital was designated as a quaran-
tine station laboratory and was thus a treatment hub for 
pandemic H1N1/09. We began laboratory testing for pan-
demic H1N1/09 on September 1, 2009. 
Nose and/or throat swabs were collected from almost all 
subjects with ILI. Infection with pandemic H1N1/09 was 
confirmed via real-time reverse transcriptase-polymerase 
chain reaction (RT-PCR, RealTime Ready influenza A/H1N1 
Detection set, Roche Diagnostics GmbH, Mannheim, Ger-
many) and/or multiplex RT-PCR (Multiplex FluA ACE Sub-
typing, Seegene, Inc., Seoul, Korea). 
Fig. 1. Laboratory-confirmed cases of pandemic H1N1/09 influenza reported at Kyung Hee University Hospital between September 1 and 
December 31, 2009.
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1.304-3.296, p=0.002), and sneeze (OR 2.543, 95% CI 
1.148-5.632, p=0.021) than patients with ILI. In multivariate 
analysis of the ≥18 age group, a fever of ≥37.8°C (OR 
4.388, 95% CI 2.885-6.674, p<0.001) and cough (OR 2.677, 
95% CI 1.779-4.030, p<0.001) were more frequent, and old-
er age (OR 0.960, 95% CI 0.945-0.974, p<0.001) was less 
frequent in patients with pandemic H1N1/09. Interestingly, 
in contrast with the results of univariated analyses, the sig-
nificant variables were not largely different except for 
sneeze (<18 age group, only) and age (≥18 age group, only), 
between the two groups.
A previous study8 reported that those with confirmed 
pandemic H1N1/09 were more likely to report feverishness, 
chills, or joint stiffness (OR 3.8, 95% CI 1.6-9.0) and rhi-
norrhea or nasal congestion (OR 2.5, 95% CI 1.2-5.3), and 
were also more likely to have ≥38.1°C fever (OR 6.7, 95% 
CI 2.7-16.7) compared to those with acute respiratory ill-
ness. Moreover, the clinical features of infection with pan-
demic H1N1/09 are similar to those of seasonal influen-
za.9-11 Subjects with pandemic H1N1/09 influenza tended to 
have fever, cough, shortness of breath, myalgia, and fatigue, 
all similar symptoms to those suffering seasonal influenza. 
Symptoms of 2009 pandemic H1N1 in children are simi-
lar to those of seasonal influenza; for example, fever, cough, 
sore throat, and myalgia.7,10-11 Other symptoms (such as di-
arrhea or vomiting) have occasionally been reported in chil-
dren and in less than 5% of adults during periods of peak 
seasonal influenza incidence.12 Another study10 reported no 
significant differences in these symptoms between children 
and adults with pandemic H1N1/09. 
onset of their illness, and those who had been sick for more 
than seven days. A total of 1,059 outpatients were include 
in this study, and of these, 586 patients were confirmed to 
have the pandemic H1N1/09 by laboratory test. 
In addition, we investigated the age distribution of pan-
demic H1N1/09 as well as the positivity rate according to 
age distribution (Fig. 2). Approximate numbers of infections 
peaked in two age groups: the pediatric and adult age groups. 
We compared patients with pandemic H1N1/09 and those 
with ILI, and then compared those groups divided by age 
(<18 years and ≥18 years) using stratified analysis, Cochran 
Mantel-Haenzel tests (Table 1). In the latter cases, there were 
differences in significant variables for distinguishing charac-
teristics of pandemic H1N1/09 between the two groups (<18 
age group, only: sore throat; ≥18 age group, only: age, co-
mobidities, risk of age, and myalgia).
Multivariate analysis (Table 2) of the whole age group, 
suggested that subjects with confirmed pandemic H1N1/09 
were less likely to be older [odds ratio (OR) 0.975, 95% 
confidence interval (CI) 0.966-0.984, p<0.001] and to have 
at least one of the following co-morbidities: age <5 or ≥65 
years, a history of contact (OR 0.611, 95% CI 0.464-0.805, 
p<0.001), and were also more likely to have a fever of   
≥37.8°C (OR 3.567, 95% CI 2.655-4.792, p<0.001), cough 
(OR 2.290, 95% CI 1.692-3.101, p<0.001), and myalgia 
(OR 1.599, 95% CI 1.1093-2.223, p=0.014) than subjects 
suffering ILI. However, multivariate analysis in the <18 age 
group, suggested that subjects with pandemic H1N1/09 
were more likely to have a fever of ≥37.8°C (OR 3.142, 
95% CI 2.041-4.835, p<0.001), cough (OR 2.073, 95% CI 
Fig. 2. Age distribution of numbers of infections (columns) and positivity rate (line) during the 2009 H1N1 influenza pandemic.
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Table 1. Clinical Characteristics of Subjects with the Pandemic H1N1/09 Influenza and Those with Influenza-Like Illness by Age 
Patients characteristics  ILI (n=473)
% (n) 
H1N1/09 
(n=586)
% (n)
p
<18 yrs (n=470)
p
≥18 yrs (n=589)
p ILI (n=180)
% (n) 
H1N1/09 
(n=290)
% (n)
ILI (n=293)
% (n) 
H1N1/09 
(n=296)
% (n)
Age in yrs, mean±SD 25.95±18.29 18.52±13.59 <0.001 7.79±4.53 7.96±4.82   0.703 29.03±11.05 36.99±14.31 <0.001
Gender,  M : F 235 : 238 272 : 314   0.290 105 : 75 151 : 139   0.215 130 : 163 121 : 175   0.406
Risk factors for severe influenza infection
Co-morbidities 14.0 (66/473)   7.8 (46/586)    0.001   5.6 (10/180)   4.8 (14/290)   0.830 19.1 (56/293) 10.8 (32/296)   0.005
    Type of co-morbidities
        Diabetes   3.4 (16/473)   1.0 (6/586)   0.0 (0/180)   0.0 (0/290)   5.5 (16/293)   2.0 (6/296)
        Chronic pulmonary 
          diseases*   2.5 (12/473)   1.7 (10/586)   3.9 (7/180)   1.7 (5/290)   1.7 (5/293)   1.7 (5/296)
        Chronic 
          cardiovascular diseases
†   3.4 (16/473)   1.0 (6/586)   0.0 (0/180)   1.0 (3/290)   5.5 (16/293)   1.0 (3/296)
        Chronic renal diseases
‡   2.1 (10/473)   0.6 (5/586)   1.1 (2/180)   0.3 (1/290)   2.7 (8/293)   1.4 (4/296)
        Chronic liver diseases
§   1.3 (6/473)   0.6 (5/586)   0.0 (0/180)   0.0 (0/290)   2.0 (6/293)   1.7 (5/296)
        Cancer or immuno-
          compromised state\\   3.0 (14/473)   1.5 (9/586)   0.0 (0/180)   0.7 (2/290)   4.8 (14/293)   2.4 (7/296)
        Neurodevelopmental 
          disorders
¶   0.2 (1/473)   0.3 (2/586)   0.6 (1/180)   0.3 (1/290)   0.0 (0/293)   0.0 (0/296)
        Pregnancy    0.6 (3/473)   0.5 (3/586)   0.0 (0/180)   0.0 (0/290)   1.0 (3/293)   1.0 (3/296)
        ≥2 co-morbidities    2.3 (11/473)   0.5 (3/586)   0.0 (0/180)   0.0 (0/290)   3.8 (11/293)   1.0 (3/296)
Age <5 or ≥65 yrs 16.9 (80/473) 14.5 (85/586)   0.283 34.4 (62/180) 27.6 (80/290)   0.122   6.1 (18/293)   1.7 (5/296)   0.005
History of contact with other 
  H1N1/09  identified 
  individuals
27.9 (132/473) 16.6 (97/586) <0.001 28.3 (51/180) 12.8 (37/290) <0.001 27.6 (81/293) 20.3 (60/296)   0.042
    Exposure site   0.054   0.126   0.150
        School (preschool) 26.6 (34/128) 42.0 (37/88) 37.5 (18/48) 60.0 (21/35) 19.3 (16/83) 30.2 (16/53)
        Home 52.3 (67/128) 34.0 (30/88) 52.1 (25/48) 34.3 (12/35) 54.2 (45/83) 34.0 (18/53)
        Military      0 (0/128)   1.1 (1/88)   0.0 (0/48)   0.0 (0/35)   0.0 (0/83)   1.9 (1/53)
        Hospital   5.5 (7/128)   3.4 (3/88)   0.0 (0/48)   0.0 (0/35)   8.4 (7/83)   5.7 (3/53)
        Workplace   7.8 (10/128) 12.5 (11/88)   0.0 (0/48)   0.0 (0/35) 12.0 (10/83) 20.8 (11/53)
        Others   7.8 (10/128)   6.8 (6/88) 10.4 (5/48)   5.7 (2/35)   6.0 (5/83)   7.5 (4/53)
Co-morbidities, age <5 or 
  ≥65 yrs, or history of 
  contact
48.4 (229/473) 34.5 (202/586) <0.001 56.7 (102/180) 40.0 (116/290)   0.001 43.3 (127/293) 29.1 (86/296) <0.001
Fever °C, mean±SD 37.04±0.84 37.71±0.93 <0.001 37.13±0.97 37.79±0.96 <0.001 36.98±0.80 37.63±0.89 <0.001
    ≥37.8°C 20.0 (90/451) 50.7 (296/584) <0.001 26.4 (47/178) 52.9 (153/289) <0.001 15.8 (43/273) 48.5 (143/295) <0.001
Fever for ≥3 days   7.2 (32/445)   7.9 (46/585)   0.686 12.0 (19/158) 11.8 (34/289)   1.000   4.5 (13/287)   4.1 (12/296)   0.840
Cough 60.7 (287/473) 80.5 (472/586) <0.001 67.8 (122/180) 80.3 (233/290)   0.003 56.3 (165/293) 80.7 (239/296) <0.001
Rhinorrhea 42.9 (203/473) 49.7 (291/586)   0.029 41.7 (75/180) 53.1 (154/290)   0.018 43.7 (128/293) 46.3 (137/296)   0.562
Sneeze   9.1 (43/473)   8.9 (52/586)   0.902   5.6 (10/180) 10.7 (31/290)   0.064 11.3 (33/293)   7.1 (21/296)   0.088
Nasal obstruction 11.6 (55/473) 12.5 (73/586)   0.681   9.4 (17/180) 11.0 (32/290)   0.643 13.0 (38/293) 13.9 (41/296)   0.809
Sore throat 47.6 (225/473) 50.5 (296/586)   0.341 30.6 (55/180) 41.7 (121/290)    0.019 58.0 (170/293) 59.1 (175/296)   0.802
Headache 31.7 (150/473) 36.5 (214/586)   0.102 18.9 (34/180) 26.6 (37/290)    0.059 39.6 (116/293) 46.3 (137/296)   0.114
Myalgia 17.3 (82/473) 23.5 (138/586)   0.013   3.3 (6/180)   5.9 (17/290)    0.274 25.9 (76/293) 40.9 (121/296) <0.001
Diarrhea   3.4 (16/473)   2.2 (13/586)   0.248   1.1 (2/180)   1.7 (5/290)   0.713   4.8 (14/293)   2.7 (8/296)   0.200
Vomiting   2.3 (11/473)   4.8 (28/586)   0.035   2.8 (5/180)   8.6 (25/290)   0.011   2.0 (6/293)   1.0 (3/296) <0.001
Nausea   2.7 (13/473)   3.9 (23/586)   0.294   2.8 (5/180)   3.8 (11/290)   0.613   2.7 (8/293)   4.1 (12/296)   0.496Outpatients with 2009 Pandemic H1N1
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of investigation. This study was conducted during the miti-
gation period, between September and December 2009. 
Therefore, active outbreak control strategies such as school 
closures, mass vaccination, and an anti-viral drug regimen 
had been applied, and sufficient health information had 
been provided to the public. 
We assessed validation of sensitivity, specificity, AUC, 
PLR, NLR, PPV, and NPV for key variables significantly 
associated with pandemic H1N1/09 infection (Table 3). 
However, considering the sensitivity, PLR, and PPV togeth-
er, it was difficult to determine the best criteria for clinical 
diagnosis of pandemic H1N1/09 in outpatients, likely due 
to its non-specific presentation. We found no clear criteria 
for having a higher pretest probability (PLR ≥5 and NLR ≤ 
0.2) in this study, especially considering the PLR and NLR 
from a previous study.16 
Several other studies have suggested that young patients 
constituted a higher proportion of those positive for pan-
demic H1N1/09.2,4,5,13-15 This may have been due to an out-
break of pandemic H1N1/09 in preschools or schools. In 
the present study, subjects with pandemic H1N1/09 with a 
history of contact with other pandemic H1N1/09-infected 
individuals accounted for 16.6% of the relevant group. Of 
those subjects <18 years of age, 12.8% had a history of 
contact with other infected subjects; these exposures oc-
curred mainly at school (60.0%) and at home (34.3%). 
Unlike those suffering from ILI, all subjects with con-
firmed pandemic H1N1/09 fulfilled at least one of the follow-
ing conditions: age <5 or ≥65 years, or a history of contact 
(48.4% vs. 34.5%, p<0.001) identified via logistic regression 
analysis. These findings differ from those of other studies.9,10 
The difference may be attributed, at least in part, to the time 
Table 1. Continued 
Patients characteristics  ILI (n=473)
% (n) 
H1N1/09 
(n=586)
% (n)
p
<18 yrs (n=470)
p
≥18 yrs (n=589)
p ILI (n=180)
% (n) 
H1N1/09 
(n=290)
% (n)
ILI (n=293)
% (n) 
H1N1/09 
(n=296)
% (n)
Abdominal pain   3.0 (14/473)   2.7 (16/586)   0.823   3.9 (7/180)   3.8 (11/290)   1.000   2.4 (7/293)   1.7 (5/296)   0.575
Loss of appetite   0.6 (3/473)   2.4 (16/586)   0.027   0.6 (1/180)   2.8 (8/290)   0.163   0.7 (2/293)   2.0 (6/296)   0.286
ILI, influenza like illness.
Statistical analysis of the clinical and laboratory characteristics of patients was conducted via t-tests for quantitative data, chi-square or Fisher’s exact 
tests for qualitative data depending on the anticipated cell number, and via Cochran Mantel-Haenzel tests for investigating a confounding variable of age 
(dividing into <18 age- group and ≥18 age-group).
*Includes chronic obstructive lung disease, asthma, bronchiectasis, bronchopulmonary dysplasia, etc.
†Includes congestive heart failure, ischemic heart disease, valvular heart disease, congenital heart disease, etc.
‡Includes nephritic syndrome, chronic renal failure, kidney transplantation status, etc. 
§Includes liver cirrhosis, liver transplantation status, etc.
\\Includes cancer, immunosuppressive drugs, human immunodeficiency virus (HIV) infection, chemotherapy, etc.
¶Includes mental retardation, cerebral palsy, etc.
Table 2. Multivariate Logistic Regression Analyses Comparing Patients with the Pandemic H1N1/09 Influenza and Those with 
Influenza-Like Illness
Variables
Total (n=1,059) <18 yrs (n=470) ≥18 yrs (n=589)
ILI (n=473) vs. H1N1/09 (n=586) ILI (n=180) vs. H1N1/09 (n=290) ILI (n=293) vs. H1N1/09 (n=296)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age 0.975 (0.966-0.984) <0.001 0.960 (0.945-0.974) <0.001
Co-morbidities*, 
  age <5 or ≥65 yrs, 
  or history of contact
0.611 (0.464-0.805) <0.001
Fever, ≥37.8°C 3.567 (2.655-4.792) <0.001 3.142 (2.041-4.835) <0.001 4.388 (2.885-6.674) <0.001
Cough 2.290 (1.692-3.101) <0.001 2.073 (1.304-3.296)   0.002 2.677 (1.779-4.030) <0.001
Myalgia 1.559 (1.093-2.223)   0.014
Sneeze 2.543 (1.148-5.632)   0.021
ILI, influenza like illness; OR, odds ratios; CI, confidence interval.
Multivariate logistic regression analyses were conducted via the ‘backward (wald) stepwise’ method. Only variables with p<0.1 in univariate analyses 
were included. 
*Includes diabetes, chronic pulmonary diseases, chronic cardiovascular diseases, chronic renal diseases, chronic liver diseases, cancer or immunocompro-
mised state, neurodevelopmental disorders, pregnancy, or having ≥2 these co-morbidities (Table 1).Kyung Sun Park, et al.
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Table 3. Sensitivity, Specificity, AUC, PLR, NLR, PPV, and NPV of Combinations of Symptoms and Signs for Distinguishing Pan-
demic H1N1/09 
Sensitivity 
(95% CI)
Specificity 
(95% CI)
AUC 
(95% CI)
PLR 
(95% CI)
NLR 
(95% CI)
PPV 
(95% CI)
NPV 
(95% CI)
Whole age
    Physicians’ 
      determination
79.86 
(76.4-83.0)
41.23 
(36.8-45.8)
0.605 
(0.575-0.635)
1.36 
(1.2-1.5)
0.49 
(0.4-0.6)
62.7 
(59.2-66.2)
62.3 
(56.7-67.7)
    KCDC criteria  47.95 
(43.8-52.1)
83.93 
(80.3-87.1)
0.659 
(0.630-0.688)
2.98 
(2.7-3.3)
0.62 
(0.5-0.8)
78.7 
(74.1-82.8)
56.6 
(52.8-60.3)
    Fever (≥37.8°C) 50.68 
(46.5-54.8)
80.04 
(76.1-83.6)
0.654 
(0.624-0.683)
2.54 
(2.3-2.8)
0.62 
(0.5-0.8)
76.7 
(72.1-80.8)
55.6 
(51.7-59.5)
    Cough 80.55
(77.1-83.7)
39.32 
(34.9-43.9)
0.599 
(0.569-0.629)
1.33 
(1.2-1.5)
0.49 
(0.4-0.6)
62.2 
(58.6-65.7)
62.0 
(56.2-67.5)
    Myalgia 23.55 
(20.2-27.2)
82.66 
(78.9-86.0)
0.531 
(0.500-0.561)
1.36 
(1.2-1.6)
0.92 
(0.8-1.1)
62.7 
(56.0-69.1)
46.6 
(43.2-50.0)
    Fever (≥37.8°C)+
      cough
41.03 
(37.0-45.1)
88.44 
(85.2-91.2)
0.647 
(0.618-0.676)
3.55 
(3.2-3.9)
0.67
 (0.5-0.9)
81.6 
(76.7-85.9)
54.5 
(50.9-58.1)
    Fever (≥37.8°C)+
      myalgia
13.50 
(10.8-16.5)
95.96 
(93.8-97.5)
0.547 
(0.517-0.578)
3.34 
(2.7-4.1)
0.90 
(0.6-1.4)
80.6 
(71.4-87.9)
47.1 
(43.9-50.3)
    Fever (≥37.8°C)+
      cough or myalgia
42.32 
(38.3-46.4)
87.08 
(83.7-90.0)
0.647 
(0.617-0.676)
3.27 
(3.0-3.6)
0.66 
(0.5-0.8)
80.3 
(75.4-84.5)
54.9 
(51.2-58.5)
    Cough+myalgia 19.97 
(16.8-23.4)
88.58 
(85.4-91.3)
0.543 
(0.512-0.573)
1.75 
(1.5-2.1)
0.90 
(0.7-1.2)
68.4 
(60.9-75.3)
47.2 
(43.9-50.5)
    Cough+fever (≥37.8°C) 
      or myalgia
48.63 
(44.5-52.8)
79.70 
(75.8-83.2)
0.599 
(0.569-0.629)
2.40 
(2.2-2.6)
0.64 
(0.5-0.8)
74.8 
(70.1-79.1)
55.6 
(51.8-59.4)
    Myalgia+fever (≥37.8°C) 
      or cough
21.16 
(17.9-24.7)
87.10 
(83.7-90.0
0.531 
(0.500-0.561)
1.64 
(1.4-1.9)
0.91 
(0.7-1.1)
67.0 
(59.7-73.7)
47.1 
(43.8-50.5)
    Fever (≥37.8°C) or 
      cough
90.26 
(87.6-92.5)
31.26 
(27.1-35.7)
0.608 
(0.577-0.637)
1.31 
(1.1-1.5)
0.31 
(0.2-0.4)
62.2 
(58.8-65.5)
71.9 
(65.2-78.0)
    Fever (≥37.8°C) or 
      myalgia
60.51 
(56.4-64.5)
67.45 
(63.0-71.7)
0.640 
(0.610-0.669)
1.86 
(1.7-2.0)
0.59 
(0.5-0.7)
69.8 
(65.6-73.8)
57.8 
(53.6-62.0)
    Myalgia or cough 50.68 
(46.5-54.8)
80.04 
(76.1-83.6)
0.654 
(0.624-0.683)
2.54 
(2.3-2.8)
0.62 
(0.5-0.8)
76.7 
(72.1-80.8)
55.6 
(51.7-59.5)
    Fever (≥37.8°C), cough  
      or myalgia 
92.32 
(89.9-94.3)
27.12 
(23.2-31.4)
0.597 
(0.567-0.627)
1.27 
(1.1-1.5)
0.28 
(0.2-0.4)
61.1 
(57.8-64.4)
74.0 
(66.8-80.4)
<18 yrs
    Fever (≥37.8°C) 52.94 
(47.0-58.8)
73.60 
(66.5-79.9)
0.633 
(0.587-0.677)
2.01 
(1.7-2.3)
0.64 
(0.5-0.8)
76.5 
(70.0-82.2)
49.1 
(42.9-55.2)
    Cough 80.34 
(75.3-84.8)
32.22 
(25.5-39.6)
0.563 
(0.517-0.608)
1.19 
(1.0-1.5)
0.61 
(0.5-0.8)
65.6 
(60.4-70.6)
50.4 
(40.9-59.9)
    Sneeze 10.69 
(7.4-14.8)
94.44 
(90.0-97.3)
0.526 
(0.479-0.572)
1.92 
(1.4-2.7)
0.95 
(0.5-1.7)
75.6 
(59.7-87.6)
39.6 
(35.0-44.4)
    Fever (≥37.8°C)+cough 40.69 
(35.0-46.6)
83.15 
(76.8-88.3)
0.619 
(0.573-0.663)
2.41
 (2.1-2.8)
0.71 
(0.5-1.0)
79.7 
(72.3-85.9)
46.2 
(40.7-51.9)
    Fever (≥37.8°C)+sneeze 4.83 
(2.7-8.0)
100.00 
(97.9-100.0)
0.524 
(0.478-0.570) NC (NC) 0.95 
(NC)
100.0 
(76.8-100.0)
39.2 
(34.7-43.9)
    Fever (≥37.8°C)+cough 
      or sneeze
42.07 
(36.3-48.0)
83.33 
(77.1-88.5)
0.627 
(0.582-0.671)
2.52 
(2.2-2.9)
0.70 
(0.5-1.0)
80.3 
(73.0-86.3)
47.2 
(41.6-52.8)
    Cough+sneeze 7.24 
(4.5-10.9)
95.00 
(90.7-97.7)
0.511 
(0.465-0.557)
1.45 
(1.0-2.2)
0.98 
(0.5-1.8)
70.0 
(50.6-85.3)
38.9 
(34.3-43.6)
    Cough+fever (≥37.8°C) 
      or sneeze
44.48 
(38.7-50.4)
78.33 
(71.6-84.1)
0.614 
(0.568-0.658)
2.05 
(1.8-2.4)
0.71 
(0.5-1.0)
76.8 
(69.7-82.9)
46.7 
(41.0-52.5)
    Sneeze+fever (≥37.8°C) 
      or cough
8.62 
(5.7-12.5)
95.00 
(90.7-97.7)
0.518 
(0.472-0.564)
1.72 
(1.2-2.5)
0.96 
(0.5-1.8)
73.5 
(55.6-87.1)
39.2 
(34.6-44.0)Outpatients with 2009 Pandemic H1N1
Yonsei Med J   http://www.eymj.org   Volume 53   Number 1   January 2012 219
notable absence of data from other laboratory tests and im-
aging examinations in that study, we could not assess these 
variables to diagnose pandemic H1N1/09. Our results sug-
gested that there was a limit to the ability to distinguish pan-
demic H1N1/09 infection from ILI by only symptoms or 
signs, because of somewhat lower sensitivity, PLR, and 
PPV. Therefore, we propose that the use of laboratory con-
firmatory testing is necessary to diagnose infection with 
pandemic H1N1/09. 
The KCDC reported that the incidence of ILI and con-
sumption of antiviral agents peaked in early November. 
Following vaccination of health care workers on October 
27, 2009, approximately 12 million people were vaccinated 
in Korea.2 One previous study18 reported that this rapid vac-
cination was the most important factor in controlling the 
spread of pandemic influenza in Korea. However, our study 
could not include an evaluative vaccination history because 
most medical charts were missing these data. Additionally, 
this study is limited by its retrospective design and single-
center origin. However, it is worth noting that large numbers 
of subjects from a single center were analyzed, and these 
data should prove useful to local influenza control centers.
In conclusion, our analysis suggested that the clinical 
characteristics of infection with pandemic H1N1/09 are in-
distinguishable from those of influenza-like illness in many 
respects. Moreover, the accuracy and predictability of crite-
ria that included only symptoms or signs were not sufficient 
In the whole age group, the sensitivity of  “fever (≥37.8°C) 
plus cough” (41.03%, 95% CI 37.1-45.1) was lower than that 
of the KCDC criteria, whereas the PLR (3.55, 95% CI 3.2-
3.9) and PPV (81.6, 95% CI 76.7-85.9) of this criterion were 
higher than those of KCDC criteria. Interestingly, most clini-
cal physicians’ determinations of pandemic H1N1/09 were 
not compliant with the KCDC criteria, so the accuracy and 
predictability insofar as sensitivity, specificity, PLR, NLR, 
PPV, or NPV were different from those of the KCDC crite-
ria. This indicates that the KCDC criteria were not actually 
sufficient for clinicians to distinguish pandemic H1N1/09 
from ILI. 
In the <18 age group, the criterion of  “fever (≥37.8°C) plus 
cough or sneeze” was the most effective (sensitivity: 42.07%, 
95% CI 36.3-48.0; PLR: 2.52, 95% CI 2.2-2.9; PPV; 80.3, 
95% CI 73.0-86.3). In the ≥18 age group, the criteria of  “fe-
ver (≥37.8°C) plus cough” was the most effective (sensitivi-
ty: 41.36%, 95% CI 35.7-47.2; PLR: 4.98, 95% CI 4.3-5.7; 
PPV; 83.6, 95% CI 55.8-65.1).
A previous study17 suggested the combination of cough 
plus fever or myalgia (sensitivity 73.95, PPV 66.4%) as the 
diagnostic criteria of pandemic H1N1/09 infection because 
of its higher sensitivity and PPV than those of the KCDC, 
WHO, or ILI criteria. Another previous study8 reported that 
the absence of leukocytosis combined with the WHO crite-
ria was the best criteria (PLR 7.8, 95% CI 3.5-17.5) in diag-
nosing pandemic H1N1/09. However, because there was a 
Table 3. Continued
Sensitivity 
(95% CI)
Specificity 
(95% CI)
AUC 
(95% CI)
PLR 
(95% CI)
NLR 
(95% CI)
PPV 
(95% CI)
NPV 
(95% CI)
    Fever (≥37.8°C) or 
      cough
92.76 
(89.1-95.5)
22.47 
(16.6-29.3)
0.576 
(0.530-0.621)
1.20 
(0.9-1.6)
0.32 
(0.2-0.5)
66.1 
(61.3-70.7)
65.6 
(52.3-77.3)
    Fever (≥37.8°C) or 
      sneeze
58.62 
(52.7-64.3)
67.98 
(60.6-74.8)
0.633 
(0.588-0.677)
1.83 
(1.6-2.1)
0.61 
(0.5-0.8)
74.9 
(68.7-80.4)
50.2 
(43.7-56.7)
    Cough or sneeze 83.79 
(79.0-87.8)
31.67 
(24.9-39.0)
0.577 
(0.531-0.622)
1.23 
(1.0-1.5)
0.51 
(0.4-0.7)
66.4 
(61.3-71.2)
54.8 
(44.7-64.6)
    Fever (≥37.8°C), cough 
      or sneeze 
94.83 
(91.6-97.1)
22.78 
(16.9-29.6)
0.588 
(0.542-0.633)
1.23 
(0.9-1.6)
0.23 
(0.1-0.4)
66.4 
(61.7-71.0)
73.2 
(59.6-84.3)
≥18 yrs
    Fever (≥37.8°C) 48.47 
(42.6-54.3)
84.25 
(79.4-88.4)
0.664 
(0.623-0.702)
3.08 
(2.7-3.5)
0.61 
(0.5-0.8)
76.9 
(70.2-82.7)
60.2 
(55.1-65.2)
    Fever (≥37.8°C)+cough 41.36 
(35.7-47.2)
91.70 
(87.9-94.6)
0.665 
(0.625-0.703)
4.98 
(4.3-5.7)
0.64 
(0.4-0.9)
83.6 
(76.5-89.2)
60.5 
(55.8-65.1)
    Fever (≥37.8°C) or 
      cough
87.80 
(83.5-91.3)
36.68 
(31.1-42.5)
0.622 
(0.582-0.662)
1.39 
(1.2-1.6)
0.33 
(0.2-0.5)
58.6 
(53.8-63.2)
74.6 
(66.7-81.6)
KCDC, Korea Centers for Disease Control and Prevention; AUC, area under the ROC curve; PLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, 
positive predictive value; NPV, negative predictive value; CI, confidence interval; NC, not calculated.
The KCDC criteria for suspicion of pandemic H1N1/09 infection were cases in which patients suffered from an unexplained fever (defined as an ear tem-
perature ≥37.8°C or antipyretics within 12 hours before hospital visit) within seven days before hospital visit and displayed symptoms such as a cough, 
sore throat, rhinorrhea, or nasal obstruction. Kyung Sun Park, et al.
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ysis of new influenza A (H1N1) cases. PLoS One 2009;4:e8453.
9. Chang YS, van Hal SJ, Spencer PM, Gosbell IB, Collett PW. 
Comparison of adult patients hospitalised with pandemic (H1N1) 
2009 influenza and seasonal influenza during the “PROTECT” 
phase of the pandemic response. Med J Aust 2010;192:90-3.
10. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie 
J, et al. Hospitalized patients with 2009 H1N1 influenza in the Unit-
ed States, April-June 2009. N Engl J Med 2009;361:1935-44. 
11. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Her-
nandez M, Quiñones-Falconi F, Bautista E, et al. Pneumonia and 
respiratory failure from swine-origin influenza A (H1N1) in Mexi-
co. N Engl J Med 2009;361:680-9.
12. Nicholson KG. Clinical features of influenza. Semin Respir Infect 
1992;7:26-37.
13. Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, Koh GC, et al. 2009 
influenza A (H1N1) seroconversion rates and risk factors among 
distinct adult cohorts in Singapore. JAMA 2010;303:1383-91.
14. Torres JP, O’Ryan M, Herve B, Espinoza R, Acuña G, Mañalich J, 
et al. Impact of the novel influenza A (H1N1) during the 2009 au-
tumn-winter season in a large hospital setting in Santiago, Chile. 
Clin Infect Dis 2010;50:860-8.
15. Choi WJ, Kim WY, Kim SH, Oh BJ, Kim W, Lim KS, et al. Clini-
cal characteristics of pneumonia in hospitalized patients with novel 
influenza A (H1N1) in Korea. Scand J Infect Dis 2010;42:311-4.
16. Jaeschke R, Guyatt GH, Sackett DL. Users’ guides to the medical 
literature. III. How to use an article about a diagnostic test. B. 
What are the results and will they help me in caring for my pa-
tients? The Evidence-Based Medicine Working Group. JAMA 
1994;271:703-7.
17. Kim CO, Nam CM, Lee DC, Han SH, Lee JW. Clinical predictors 
of novel influenza A (H1N1) infection in Korea. Yonsei Med J 
2010;51:895-900.
18. Suh M, Lee J, Chi HJ, Kim YK, Kang DY, Hur NW, et al. [Math-
ematical modeling of the novel influenza A (H1N1) virus and 
evaluation of the epidemic response strategies in the Republic of 
Korea]. J Prev Med Public Health 2010;43:109-16.
to diagnose pandemic H1N1/09 infection. Therefore, a com-
bination of clinical diagnosis and confirmatory laboratory 
tests is required for accurate diagnosis of pandemic H1N1/09 
infection.
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